These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 20733267)

  • 21. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia.
    Dujovne CA; Ettinger MP; McNeer JF; Lipka LJ; LeBeaut AP; Suresh R; Yang B; Veltri EP;
    Am J Cardiol; 2002 Nov; 90(10):1092-7. PubMed ID: 12423709
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lipid-lowering effects of colesevelam HCl in combination with ezetimibe.
    Bays H; Rhyne J; Abby S; Lai YL; Jones M
    Curr Med Res Opin; 2006 Nov; 22(11):2191-200. PubMed ID: 17076980
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of ezetimibe on markers of synthesis and absorption of cholesterol in high-risk patients with elevated C-reactive protein.
    Barbosa SP; Lins LC; Fonseca FA; Matos LN; Aguirre AC; Bianco HT; Amaral JB; França CN; Santana JM; Izar MC
    Life Sci; 2013 May; 92(14-16):845-51. PubMed ID: 23507424
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of ezetimibe as monotherapy or combination therapy in hypercholesterolemic patients with and without diabetes.
    Kishimoto M; Sugiyama T; Osame K; Takarabe D; Okamoto M; Noda M
    J Med Invest; 2011 Feb; 58(1-2):86-94. PubMed ID: 21372492
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials.
    Morrone D; Weintraub WS; Toth PP; Hanson ME; Lowe RS; Lin J; Shah AK; Tershakovec AM
    Atherosclerosis; 2012 Aug; 223(2):251-61. PubMed ID: 22410123
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lipoprotein effects of combined ezetimibe and colesevelam hydrochloride versus ezetimibe alone in hypercholesterolemic subjects: a pilot study.
    Knopp RH; Tsunehara C; Retzlaff BM; Fish B; Nguyen H; Anderson S; Nguyen T
    Metabolism; 2006 Dec; 55(12):1697-703. PubMed ID: 17142146
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Double-dose pravastatin versus add-on ezetimibe with low-dose pravastatin - effects on LDL cholesterol, cholesterol absorption, and cholesterol synthesis in Japanese patients with hypercholesterolemia (PEAS study).
    Sasaki J; Otonari T; Sawayama Y; Hata S; Oshima Y; Saikawa T; Biro S; Kono S;
    J Atheroscler Thromb; 2012; 19(5):485-93. PubMed ID: 22659533
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of dalcetrapib, a CETP modulator, on non-cholesterol sterol markers of cholesterol homeostasis in healthy subjects.
    Niesor EJ; Chaput E; Staempfli A; Blum D; Derks M; Kallend D
    Atherosclerosis; 2011 Dec; 219(2):761-7. PubMed ID: 21982411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
    Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E;
    Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of ezetimibe, simvastatin and ezetimibe/simvastatin on correlations between apolipoprotein B, LDL cholesterol and non-HDL cholesterol in patients with primary hypercholesterolemia.
    Farnier M; Guyton JR; Jensen E; Polis AB; Johnson-Levonas AO; Brudi P
    Atherosclerosis; 2013 Aug; 229(2):415-22. PubMed ID: 23880197
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study).
    Robinson JG; Ballantyne CM; Grundy SM; Hsueh WA; Parving HH; Rosen JB; Adewale AJ; Polis AB; Tomassini JE; Tershakovec AM
    Am J Cardiol; 2009 Jun; 103(12):1694-702. PubMed ID: 19539078
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Change in the cholesterol metabolism associated with the combined inhibition of synthesis and absorption].
    Márk L; Paragh G
    Orv Hetil; 2007 Apr; 148(14):627-32. PubMed ID: 17403635
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients.
    Catapano AL; Davidson MH; Ballantyne CM; Brady WE; Gazzara RA; Tomassini JE; Tershakovec AM
    Curr Med Res Opin; 2006 Oct; 22(10):2041-53. PubMed ID: 17022864
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of low-fat, fermented milk enriched with plant sterols on serum lipid profile and oxidative stress in moderate hypercholesterolemia.
    Hansel B; Nicolle C; Lalanne F; Tondu F; Lassel T; Donazzolo Y; Ferrières J; Krempf M; Schlienger JL; Verges B; Chapman MJ; Bruckert E
    Am J Clin Nutr; 2007 Sep; 86(3):790-6. PubMed ID: 17823447
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ezetimibe, an inhibitor of Niemann-Pick C1-like 1 protein, decreases cholesteryl ester transfer protein in type 2 diabetes mellitus.
    Yagyu H; Nagashima S; Takahashi M; Miyamoto M; Okada K; Osuga J; Ishibashi S
    Endocr J; 2012; 59(12):1077-84. PubMed ID: 22850130
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
    Thomas GS; Cromwell WC; Ali S; Chin W; Flaim JD; Davidson M
    J Am Coll Cardiol; 2013 Dec; 62(23):2178-84. PubMed ID: 24013058
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study.
    Ballantyne CM; Abate N; Yuan Z; King TR; Palmisano J
    Am Heart J; 2005 Mar; 149(3):464-73. PubMed ID: 15864235
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia.
    Bays HE; Ose L; Fraser N; Tribble DL; Quinto K; Reyes R; Johnson-Levonas AO; Sapre A; Donahue SR;
    Clin Ther; 2004 Nov; 26(11):1758-73. PubMed ID: 15639688
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial.
    Pearson TA; Denke MA; McBride PE; Battisti WP; Brady WE; Palmisano J
    Mayo Clin Proc; 2005 May; 80(5):587-95. PubMed ID: 15887425
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis.
    Ose L; Shah A; Davies MJ; Rotonda J; Maccubbin D; Tribble D; Veltri E; Mitchel Y
    Curr Med Res Opin; 2006 May; 22(5):823-35. PubMed ID: 16709304
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.